Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Progyny, Inc. $PGNY

Universal Beteiligungs und Servicegesellschaft mbH increased its position in Progyny, Inc. (NASDAQ:PGNY) by 34.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,331 shares of the company’s stock after buying an additional 30,243 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Progyny were worth $2,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of PGNY. Integrated Quantitative Investments LLC purchased a new position in shares of Progyny during the second quarter worth approximately $793,000. Cetera Investment Advisers boosted its stake in shares of Progyny by 6.6% in the 2nd quarter. Cetera Investment Advisers now owns 45,122 shares of the company’s stock valued at $993,000 after purchasing an additional 2,809 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Progyny by 1,589.8% during the 2nd quarter. SG Americas Securities LLC now owns 131,550 shares of the company’s stock valued at $2,894,000 after purchasing an additional 123,765 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Progyny by 8.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,146 shares of the company’s stock worth $421,000 after purchasing an additional 1,417 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Progyny by 7.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 18,940 shares of the company’s stock worth $417,000 after purchasing an additional 1,292 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Activity

In other news, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the transaction, the chief financial officer owned 48,358 shares in the company, valued at $1,233,129. This represents a 30.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Peter Anevski purchased 79,500 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was acquired at an average price of $24.29 per share, for a total transaction of $1,931,055.00. Following the completion of the transaction, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at approximately $16,523,296.79. This trade represents a 13.23% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 26,698 shares of company stock valued at $667,437 in the last quarter. 9.40% of the stock is currently owned by insiders.

Progyny Stock Up 1.8%

PGNY opened at $26.33 on Tuesday. The firm has a 50 day moving average price of $21.37 and a 200-day moving average price of $22.00. Progyny, Inc. has a twelve month low of $13.86 and a twelve month high of $27.25. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 2.04 and a beta of 1.29.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The company had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. Progyny’s revenue for the quarter was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. As a group, analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Analysts Set New Price Targets

PGNY has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their target price on Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Raymond James Financial set a $28.00 price objective on Progyny in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price target (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. Finally, KeyCorp raised Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price objective for the company in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and an average target price of $27.33.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.